Published by Yale News

Researchers at the Yale School of Medicine and the VA Connecticut Healthcare System have successfully tailored a personalized treatment approach for chronic pain in a severe pain syndrome known as inherited erythromelalgia.

Inherited erythromelalgia occurs when genetic mutations cause the body’s pain-sensing system to go into high gear, leading to flare-ups of pain and burning sensations in response to seemingly benign triggers, such as warm temperature and mild exercise.

The researchers applied molecular modeling and multi-electrode array technology to find the most effective drug treatment plan for two patients, guided by the exact location of the mutation in each patient’s genome. The researchers then conducted a double-blind, placebo-controlled study in which they assessed the effect of a placebo or the drug carbamazepine on the patients’ pain perception and neural activity.

The findings of the study appear in the April 18 issue of JAMA Neurology.

Read the Full Article